Project Details
Projekt Print View

Differentiation and activation of immune cells in the tumor microenvironment: role of tumor-derived lactate in immunomodulation in vitro and in vivo

Subject Area Hematology, Oncology
Term from 2011 to 2018
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 190230491
 
Final Report Year 2019

Final Report Abstract

The tumor microenvironment modulates the activation of infiltrating cells and thereby regulates the balance between immune response and tolerance. The main findings of this project are that tumorderived lactic acid can suppress T and NK cells in vitro and in vivo which adds another piece to the tumor immune suppression puzzle. Based on these data we speculated that tumor derived lactic acid may limit the efficacy of checkpoint therapy. We demonstrated in several publications that the NSAID diclofenac blocks lactate secretion while preserving T cell effector functions which may result in a better response to checkpoint therapy. Our very recent data support this conclusion as we were able to show that diclofenac can improve checkpoint therapy in a murine breast carcinoma model. And we hope that these data will help us to get funding to confirm our findings in a clinical trial.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung